Citigroup Reiterates Buy Rating on Immunovant, Inc. (IMVT)
Citigroup maintains its buy rating on Immunovant with a $61 price target, a 58.32% upside from the current price.
Key Points
- Citigroup reiterated its buy rating on Immunovant, Inc. (IMVT) on June 30, 2026, with a price target of $61.
- Citigroup's $61 price target implies 58.32% upside from Immunovant, Inc.'s ($IMVT) current $38.53 share price.
- Shares of Immunovant traded near $38.51 on Tuesday, with a 52-week high of $39.28 and a market cap of about $7.98 billion.
- Recent insider activity included sales by key executives, while analysts like Guggenheim and B of A Securities also maintain buy ratings.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Citigroup reiterated its buy rating on Immunovant, Inc. (NasdaqGS: IMVT) on June 30, 2026. The firm maintained a price target of $61, indicating continued confidence in the biotechnology company's future prospects.
Citigroup vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Immunovant, Inc. Stock Down 6.5%
Shares of NasdaqGS:IMVT traded near $38.51 on Tuesday. Immunovant, Inc. has a market cap of approximately $7.98 billion. The company is not currently profitable, so it has no meaningful P/E ratio. Its stock has a 52-week low of $14.32 and a 52-week high of $39.28. The 50-day moving average is $31.18, while the 200-day moving average is $25.27. The company has a strong balance sheet with a current ratio of 9.09 and a quick ratio of 8.68, along with a low debt-to-equity ratio of 0.008.
$IMVT price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Immunovant, Inc.
Recent insider transactions at Immunovant included several sales by key executives. On June 26, 2026, Chief Legal Officer Christopher Van Tuyl sold 17,824 shares at an average price of $38.31. Chief Financial Officer Tiago Girao also sold 10,000 shares at a price of $38.46. In contrast, Atul Pande bought 1,500 shares at $8.43 on the same day.
Analysts Set New Price Targets
On June 30, 2026, Citigroup maintained its buy rating on Immunovant with a $61 price target. Other analysts have also shown interest in the stock. Guggenheim maintained its buy rating with a $62 target on May 26, 2026, while B of A Securities set a $43 target on May 21, 2026. The consensus among 17 analysts is a buy rating with a mean price target of $45.76.
About Immunovant, Inc.
Immunovant, Inc. is a biotechnology company based in Durham, North Carolina. The firm focuses on developing therapies for autoimmune diseases. Its pipeline includes IMVT-1402, a monoclonal antibody aimed at treating conditions such as Graves' disease, rheumatoid arthritis, and myasthenia gravis. Founded in 2018, the company employs around 315 people and is led by CEO Dr. Eric Venker.
Bottom Line
Citigroup's reiteration of its buy rating reflects ongoing confidence in Immunovant's potential. With a strong balance sheet and a robust pipeline, the company remains a key player in the biotech sector. Investors often track such analyst updates to gauge market sentiment, but it's important to remember that these are backward-looking assessments.
Get Immunovant, Inc. alerts
New 13F filings, insider trades, and analyst moves on $IMVT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.